Page 269 - Withrow and MacEwen's Small Animal Clinical Oncology, 6th Edition

248 PART III Therapeutic Modalities for the Cancer Patient

198. Pluhar GE, Grogan PT, Seiler C, et al.: Anti-tumor immune 217. Kaufman HL, Lenz HJ, Marshall J, et al.: Combination chemo-
response correlates with neurological symptoms in a dog with spon- therapy and ALVAC-CEA/B7.1 vaccine in patients with metastatic
taneous astrocytoma treated by gene and vaccine therapy, Vaccine colorectal cancer, Clin Cancer Res 14(15):4843–4849, 2008.
VetBooks.ir 199. Cheever MA, Allison JP, Ferris AS, et al.: The prioritization of can- 218. Hofbauer GF, Baur T, Bonnet MC, et al.: Clinical phase I intra-
28(19):3371–3378, 2010.
tumoral administration of two recombinant ALVAC canarypox
cer antigens: a national cancer institute pilot project for the acceler-
ation of translational research, Clin Cancer Res 15(17):5323–5337, viruses expressing human granulocyte-macrophage colony-stimu-
lating factor or interleukin-2: the transgene determines the compo-
2009. sition of the inflammatory infiltrate, Melanoma Res 18(2):104–111,
200. Smyth MJ, Dunn GP, Schreiber RD: Cancer immunosurveillance 2008.
and immunoediting: the roles of immunity in suppressing tumor 219. Spaner DE, Astsaturov I, Vogel T, et al.: Enhanced viral and
development and shaping tumor immunogenicity, Adv Immunol tumor immunity with intranodal injection of canary pox viruses
90:1–50, 2006. expressing the melanoma antigen, gp100, Cancer 106(4):890–
201. Whiteside TL: Immune responses to malignancies, J Allergy Clin 899, 2006.
Immunol 125(2 Suppl 2):S272–283, 2010. 220. Lech PJ, Russell SJ: Use of attenuated paramyxoviruses for cancer
202. U’Ren LW, Biller BJ, Elmslie RE, et al.: Evaluation of a novel therapy, Expert Rev Vaccines 9(11):1275–1302, 2010.
tumor vaccine in dogs with hemangiosarcoma, J Vet Intern Med 221. Melief CJ: Cancer immunotherapy by dendritic cells, Immunity
21(1):113–120, 2007. 29(3):372–383, 2008.
203. Hogge GS, Burkholder JK, Culp J, et al.: Preclinical development 222. Palucka K, Ueno H, Roberts L, et al.: Dendritic cells: are they
of human granulocyte-macrophage colony-stimulating factor- clinically relevant? Cancer J 16(4):318–324, 2010.
transfected melanoma cell vaccine using established canine cell 223. Palucka K, Ueno H, Banchereau J: Recent developments in cancer
lines and normal dogs, Cancer Gene Ther 6(1):26–36, 1999. vaccines, J Immunol 186(3):1325–1331, 2011.
204. Turek MM, Thamm DH, Mitzey A, et al.: Human granulocyte- 224. Slingluff Jr CL, Petroni GR, Yamshchikov GV, et al.: Clinical and
macrophage colony-stimulating factor DNA cationic-lipid com- immunologic results of a randomized phase II trial of vaccination
plexed autologous tumour cell vaccination in the treatment of using four melanoma peptides either administered in granulocyte-
canine B-cell multicentric lymphoma, Vet Comp Oncol 5(4):219– macrophage colony-stimulating factor in adjuvant or pulsed on
231, 2007. dendritic cells, J Clin Oncol 21(21):4016–4026, 2003.
205. Alexander AN, Huelsmeyer MK, Mitzey A, et al.: Development 225. Giermasz AS, Urban JA, Nakamura Y, et al.: Type-1 polarized den-
of an allogeneic whole-cell tumor vaccine expressing xenogeneic dritic cells primed for high IL-12 production show enhanced activity
gp100 and its implementation in a phase II clinical trial in canine as cancer vaccines, Cancer Immunol Immunother 58(8):1329–1336,
patients with malignant melanoma, Cancer Immunol Immunother 2009.
55(4):433–442, 2006. 226. Gyorffy S, Rodriguez-Lecompte JC, Woods JP, et al.: Bone mar-
206. Sorenmo KU, Krick E, Coughlin CM, et al.: CD40-activated B row-derived dendritic cell vaccination of dogs with naturally occur-
cell cancer vaccine improves second clinical remission and survival ring melanoma by using human gp100 antigen, J Vet Intern Med
in privately owned dogs with non-Hodgkin’s lymphoma, PLoS One 19(1):56–63, 2005.
6(8):e24167, 2011. 227. Tamura K, Yamada M, Isotani M, et al.: Induction of dendritic cell-
207. Mutwiri G, Pontarollo R, Babiuk S, et al.: Biological activity of mediated immune responses against canine malignant melanoma
immunostimulatory CpG DNA motifs in domestic animals, Vet cells, Vet J 175(1):126–129, 2008.
Immunol Immunopathol 91(2):89–103, 2003. 228. Bird RC, Deinnocentes P, Church Bird AE, et al.: An autologous
208. Liu MA: DNA vaccines: an historical perspective and view to the dendritic cell canine mammary tumor hybrid-cell fusion vaccine,
future, Immunol Rev 239(1):62–84, 2011. Cancer Immunol Immunother 60(1):87–97, 2011.
209. Bergman PJ, Camps-Palau MA, McKnight JA, et al.: Development 229. Kohler G, Milstein C: Continuous cultures of fused cells secret-
of a xenogeneic DNA vaccine program for canine malignant mela- ing antibody of predefined specificity, Nature 256(5517):495–497,
noma at the Animal Medical Center, Vaccine 24(21):4582–4585, 1975.
2006. 230. Osbourn J, Jermutus L, Duncan A: Current methods for the gen-
210. Liao JC, Gregor P, Wolchok JD, et al.: Vaccination with human eration of human antibodies for the treatment of autoimmune dis-
tyrosinase DNA induces antibody responses in dogs with advanced eases, Drug Discov Today 8(18):845–851, 2003.
melanoma, Cancer Immun 6(8), 2006. 231. Abes R, Teillaud JL: Modulation of tumor immunity by therapeu-
211. Bergman PJ, McKnight J, Novosad A, et al.: Long-term survival of tic monoclonal antibodies, Cancer Metastasis Rev 30(1):111–124,
dogs with advanced malignant melanoma after DNA vaccination 2011.
with xenogeneic human tyrosinase: a phase I trial, Clin Cancer Res 232. Paoloni M, Mazcko C, Selting K, et al.: Defining the pharmacody-
9(4):1284–1290, 2003. namic profile and therapeutic index of NHS-IL12 immunocyto-
212. Goubier A, Fuhrmann L, Forest L, et al.: Superiority of needle-free kine in dogs with malignant melanoma, PLoS One 10(6):e0129954,
transdermal plasmid delivery for the induction of antigen-specific 2015.
IFNgamma T cell responses in the dog, Vaccine 26(18):2186–2190, 233. Rosenberg SA, Yang JC, Restifo NP: Cancer immunotherapy:
2008. moving beyond current vaccines, Nat Med 10(9):909–915, 2004.
213. Bergman PJ: Cancer immunotherapy, Vet Clin North Am Small 234. Gattinoni L, Finkelstein SE, Klebanoff CA, et al.: Removal of
Anim Pract 40(3):507–518, 2010. homeostatic cytokine sinks by lymphodepletion enhances the effi-
214. Gavazza A, Lubas G, Fridman A, et al.: Safety and efficacy of a genetic cacy of adoptively transferred tumor-specific CD8+ T cells, J Exp
vaccine targeting telomerase plus chemotherapy for the therapy of Med 202(7):907–912, 2005.
canine B-cell lymphoma, Hum Gene Ther 24(8):728–738, 2013. 235. Paulos CM, Wrzesinski C, Kaiser A, et al.: Microbial translocation aug-
215. Peruzzi D, Gavazza A, Mesiti G, et al.: A vaccine targeting telom- ments the function of adoptively transferred self/tumor-specific CD8+
erase enhances survival of dogs affected by B-cell lymphoma, Mol T cells via TLR4 signaling, J Clin Invest 117(8):2197–2204, 2007.
Ther 18(8):1559–1567, 2010. 236. Dudley ME, Yang JC, Sherry R, et al.: Adoptive cell therapy for
216. von Mehren M, Arlen P, Tsang KY, et al.: Pilot study of a dual patients with metastatic melanoma: evaluation of intensive mye-
gene recombinant avipox vaccine containing both carcinoembry- loablative chemoradiation preparative regimens, J Clin Oncol
onic antigen (CEA) and B7.1 transgenes in patients with recurrent 26(32):5233–5239, 2008.
CEA-expressing adenocarcinomas, Clin Cancer Res 6(6):2219– 237. Quezada SA, Simpson TR, Peggs KS, et al.: Tumor-reactive
2228, 2000. CD4(+) T cells develop cytotoxic activity and eradicate large